NCT04893161View on ClinicalTrials.gov

A Model About the Response of Belimumab in SLE

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Belimumab

All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER